Mobile Diagnostics Without Compromise

The Challenges are Global

Clinicians need critical diagnostics earlier to empower the best, actionable care pathways.

The Value is Real

Empowered clinicians give millions the opportunity of timely treatment and improved patient outcomes.

Our Goal

Is to bring trusted diagnostics to the point of initial patient interaction, to expand access of quality healthcare to new settings, no matter where that patient interaction occurs

Nanomix Goals


Internal Link

Nanōmix Announces UK MHRA Registration for New Point of Care System

The Company announced confirmation of registration from the Medicines & Healthcare products Regulatory Agency (MHRA) of the United Kingdom for the Nanomix eLab system and the S1 Panel Cartridge.

Internal Link

Nanōmix Submits Emergency Use Authorization Application for its Rapid Point- of-Care Antigen Panel to Detect COVID-19

The Company has resubmitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test.

Internal Link

Nanōmix Completes Changes to Corporate Name and Ticker Symbol

The Company’s common shares begin trading on the OTC Market under the NNMX ticker symbol as of the opening of the Market today.